Introduction: A massive suprachoroidal haemorrhage (SCH) is a devastating complication with significant morbidity and poor visual and anatomic outcome. Conventional management is to observe for 7–14 days before surgical drainage. However, permanent structural changes in the retina can occur within this timeframe. Suprachoroidal injection of recombinant tissue plasminogen activator (TPA) may speed up clot breakdown and aid early surgical drainage. We present a case series of macula-involving massive SCH (MSCH) treated with early drainage aided by recombinant tissue plasminogen activator (r-tPA). Case Presentation: Retrospective case series of 3 patients with macula-involving MSCH treated with suprachoroidal r-tPA within 24 h of bleed and early drainage of SCH within 48 h of r-tPA injection, combined with vitrectomy and tamponade. 100 µg of recombinant TPA was injected into the SCH 24 h following initial injury in all patients. Drainage of the SCH was then performed 6–48 h after the injection of r-tPA. Early drainage was successful and visual improvement was seen in all patients. One patient had a recurrence of SCH but was successfully re-treated. Conclusion: The technique of r-tPA-assisted early drainage of SCH is safe and has promising potential to restore visual function in patients with macula-involving MSCH. Our small sample would indicate that 100 μg/0.4 mL of r-tPA injected within 24 h of bleed allows surgical drainage of SCH as early as day 2 post initial injury. Larger studies are required to investigate further which patients are likely to benefit from this treatment.

Suprachoroidal haemorrhage (SCH) is a sight-threatening complication which can occur secondary to intraocular surgery [1], melanoma [2], trauma [3], or very rarely spontaneously [4]. It can cause significant morbidity due to pain and visual impairment-associated hyphaema, vitreous haemorrhage, retinal detachment, and ocular hypertension [5]. A SCH is termed “massive” when it is large enough to expel the intraocular contents through the open wound or bring the retinal tissues into apposition (“kissing” SCH) [1] and carries a poorer visual prognosis [6]. The management of a SCH depends upon its size and symptoms. A localised asymptomatic SCH is likely to be spontaneously absorbed [7]. A massive SCH (MSCH) has a high risk of loss of vision and developing phthisis [8, 9]. Surgical drainage of MSCH may produce better anatomical outcomes, particularly when associated with retinal detachments, retinal or vitreous incarceration, persistent flat anterior chamber, or haemorrhage [3, 10]. Unfortunately, the visual function of patients treated with surgical drainage tends to remain low [6, 11]. A 7–14-day delay is typically imposed to allow the clot to liquefy and thus aid surgical drainage [5]. We hypothesise this may be partially responsible for the poor visual recovery because of the irreversible changes occurring in the retina during this time, including retinal necrosis and atrophy [7].

Tissue plasminogen activator (tPA) is a natural serine protease that functions by selectively activating fibrin-bound plasminogen to form plasmin. Plasmin, in turn, degrades fibrin to help liquefy blood clots [12]. Recombinant DNA techniques have been used to produce tPA for medicinal use. The practice of using recombinant tPA (r-tPA, alteplase) to accelerate SCH drainage has not reached widespread use due to unknown risks and side effects. Table 1 summarises cases reports in the literature where recombinant r-tPA has been used as an adjunct to hasten clot liquefaction [13‒18].

Table 1.

Summary of the published cases of r-tPA-assisted early drainage of SCH

ReferenceAge, yearsSCHTreatmentVisual acuityOutcome
causedurationr-tPA administrationsecondary procedurepreoppostopdrainagecomplications
Kurokawa [13] (2011) 92 Globe rupture <24 h ∼25 µg 20 min preop Drainage/vitrectomy/SF6 6/6+1 6/38 Partial Retinal detachment 
Akram [18] (2021) 85 Complicated cataract surgery 4 days 100 µg 3-h pre-drainage Drainage/vitrectomy. Patient kept aphakic LP 6/120 Not reported Not reported 
Fei [14] (2017) 73 Complicated cataract surgery 4 days 40 µg 24 h preop Drainage/vitrectomy/lensectomy/C3F8 LP 3/60a Complete Hyphaema resolved spontaneously 
Kunjukunju [16] (2011) 62 Post-vitrectomy for RD 12 days 100 µg 45 min preop into SCH and 100 µg into anterior chamber (dense hyphaema) Drainage/AC washout/vitrectomy/silicon oil tamponade LP 6/12 Complete Not reported 
Matsumoto [15] (2012) 32 Globe rupture 9 days 100 µg 1-h pre-drainage Drainage/vitrectomy/encircling band/silicone oil HM 6/38 Partial Retinal detachment after oil removal 
ReferenceAge, yearsSCHTreatmentVisual acuityOutcome
causedurationr-tPA administrationsecondary procedurepreoppostopdrainagecomplications
Kurokawa [13] (2011) 92 Globe rupture <24 h ∼25 µg 20 min preop Drainage/vitrectomy/SF6 6/6+1 6/38 Partial Retinal detachment 
Akram [18] (2021) 85 Complicated cataract surgery 4 days 100 µg 3-h pre-drainage Drainage/vitrectomy. Patient kept aphakic LP 6/120 Not reported Not reported 
Fei [14] (2017) 73 Complicated cataract surgery 4 days 40 µg 24 h preop Drainage/vitrectomy/lensectomy/C3F8 LP 3/60a Complete Hyphaema resolved spontaneously 
Kunjukunju [16] (2011) 62 Post-vitrectomy for RD 12 days 100 µg 45 min preop into SCH and 100 µg into anterior chamber (dense hyphaema) Drainage/AC washout/vitrectomy/silicon oil tamponade LP 6/12 Complete Not reported 
Matsumoto [15] (2012) 32 Globe rupture 9 days 100 µg 1-h pre-drainage Drainage/vitrectomy/encircling band/silicone oil HM 6/38 Partial Retinal detachment after oil removal 

Visual acuities have been converted into UK Snellen equivalent.

r-tPA, recombinant tissue plasminogen activator; LP, light perception; HM, hand movements.

aPublication states a vision of “30/60,” 3/60 is the presumed intention.

Table 2.

Summary of cases treated with r-tPA prior to surgical drainage of SCH

PatientsSCHTreatmentVisual acuityOutcome
caseage, yearscausedurationr-tPA doseprocedurepreoppostopSCHcomplications
55 Globe rupture 24 h 100/0.4 µg/mL Drainage/vitrectomy/retinopexy/SO tamponade/iris plane sutures HM CF Complete None 
48 h preop 
22 Penetrating injury/wound dehiscence 24 h 100/0.4 µg/mL Drainage/vitrectomy/retinopexy/SO tamponade HM 6/36 Complete None 
48 h preop 
89 Xen gel implant 24 h 100/0.1 µg/mL Drainage/redo vitrectomy LP LP Partial Rebleed 
6 h preop 
89 Rebleed 48 h 100/0.1 µg/mL Drainage/redo vitrectomy/PFC tamponade LP 6/15 Complete None 
6 h preop 
PatientsSCHTreatmentVisual acuityOutcome
caseage, yearscausedurationr-tPA doseprocedurepreoppostopSCHcomplications
55 Globe rupture 24 h 100/0.4 µg/mL Drainage/vitrectomy/retinopexy/SO tamponade/iris plane sutures HM CF Complete None 
48 h preop 
22 Penetrating injury/wound dehiscence 24 h 100/0.4 µg/mL Drainage/vitrectomy/retinopexy/SO tamponade HM 6/36 Complete None 
48 h preop 
89 Xen gel implant 24 h 100/0.1 µg/mL Drainage/redo vitrectomy LP LP Partial Rebleed 
6 h preop 
89 Rebleed 48 h 100/0.1 µg/mL Drainage/redo vitrectomy/PFC tamponade LP 6/15 Complete None 
6 h preop 

r-tPA, recombinant tissue plasminogen activator. HM, hand movements. CF, counting fingers. LP, light perception.

Here we present a series of cases where r-tPA has been injected into the suprachoroidal space prior to surgery to assist early drainage of macula-involving MSCH. To the best of our knowledge, this is the first case series treated with a standardised approach early drainage of SCH.

We performed retrospective review of cases with macula-involving MSCH who were treated with r-tPA prior to surgical drainage (Table 2). In each case, SCH was diagnosed based on clinical examination and confirmed by ultrasound. Procedures were performed by two vitreoretinal surgeon (S.S. and E.J.H.) in NNUH and ZNA Middelheim Hospital, respectively.

The position of SCH was carefully documented during ultrasound examination. This was then used as a guide to inject trans-scleral r-tPA into the SCH using a 25- or 27-gauge needle in aseptic setting. 24 h were allowed before starting the first stage of treatment. This was to allow maximum haemolysis through direct contact of r-tPA molecules with the blood clot and minimise the risk of rebleed. Injection of r-tPA was placed in 2 quadrants in the clock hour of the highest point of SCH as marked by ultrasound, 4–5 mm from the limbus, at 2–3 mm deep perpendicular to the sclera.

r-TPA acts by direct contact; therefore, it was divided into two injection sites 50/0.2 mL at each site to facilitate diffusion. Induced ocular hypertension was treated with topical antiglaucoma drops and systemic acetazolamide when required.

A further interval (24–48 h) was arranged before the second stage of surgery was allowed to commence. Drainage of SCH was performed via standard scleral incisions for 3 port pars plana vitrectomy (PPV) using 23-gauge MVR blade, while the intraocular infusion was placed in the anterior chamber. Following this, PPV with patient specific additional procedures and internal silicon oil tamponade was performed at the discretion of the operating surgeon.

Written informed consent was obtained from all the patients for publication of the details of their medical case and any accompanying images. Ethics approval was not required by the West of Scotland Ethics Committee as it was a retrospective study. The principles of the Declaration of Helsinki were maintained throughout the audit process.

The CARE Checklist has been completed by the authors for this case report, attached as online supplementary material (for all online suppl. material, see https://doi.org/10.1159/000545290).

Case 1

A 55-year-old pseudophakic female with a background of aniridia and with previous (prior to trauma) best corrected visual acuity (BCVA) of 6/18 presented following repaired globe rupture from 12 to 3 o’clock and total hyphaema following blunt trauma was referred to us due to macula-involving SCH confirmed on ultrasound demonstrating large macular haemorrhage, choroidal effusions of kissing configuration (Fig. 1). Her BCVA at presentation was hand movements. Injection of r-tPA 100 μg/0.4 mL into the suprachoroidal space was performed 24 h after the initial haemorrhage. Drainage of the SCH was performed 48 h later, combined with PPV, localised retinectomy of incarcerated superior retina, and a continuous 10-0 prolene retention suture in the iris plane for the oil tamponade. Postoperatively, the retina appeared flat with no residual SCH (Fig. 2). 1 year postoperatively, BCVA was counting fingers with and intraocular pressure (IOP) of 14 mm Hg.

Fig. 1.

B-USS of the preoperative appearance of case 1 demonstrating large macular haemorrhage, choroidal effusions of kissing configuration.

Fig. 1.

B-USS of the preoperative appearance of case 1 demonstrating large macular haemorrhage, choroidal effusions of kissing configuration.

Close modal
Fig. 2.

Fundus photograph of postoperative appearance of case 1, demonstrating flat retina with complete resolution of haemorrhage.

Fig. 2.

Fundus photograph of postoperative appearance of case 1, demonstrating flat retina with complete resolution of haemorrhage.

Close modal

Case 2

A 22-year-old male presented with a large limbus to limbus full-thickness central corneal wound dehiscence after a night of intoxication and vomiting. He had a previous history of surgical repair of a glass injury followed by lensectomy, PPV 4 months earlier. On examination, he had hand movement vision, flat anterior chamber, no red reflex, and MSCH on ultrasound (Fig. 3). Corneal wound closure and injection of r-tPA 100 μg/0.4 mL into the suprachoroidal space was performed 24 h after the injury by surgeon 1 (S.S.). Drainage of the SCH was carried out 48 h later and was combined with redo-PPV, silicon oil tamponade, and retinopexy. Postoperatively, the retina was flat under oil (Fig. 4). One year postoperatively, BCVA was 6/36, IOP was 17 mm Hg, and the SCH was drained completely.

Fig. 3.

B-USS of the preoperative appearance of case 2, demonstrating massive suprachoroidal haemorrhage.

Fig. 3.

B-USS of the preoperative appearance of case 2, demonstrating massive suprachoroidal haemorrhage.

Close modal
Fig. 4.

Fundus photograph of postoperative appearance of case 2, demonstrating flat retina under oil with complete resolution of haemorrhage.

Fig. 4.

Fundus photograph of postoperative appearance of case 2, demonstrating flat retina under oil with complete resolution of haemorrhage.

Close modal

Case 3

An 89-year-old male was referred from private sector because of a MSCH diagnosed 1 day after a XEN gel stent (Allergan, Dublin, CA) implantation for chronic open angle glaucoma. He presented with a flat anterior chamber, IOP of 45 mm Hg, and a MSCH. Visual acuity was light perception. Ultrasound confirmed a MSCH involving the macula. Injection of r-tPA 100 μg/0.1 mL into the suprachoroidal space was performed 24 h after the initial haemorrhage. Six hours later, a trans-scleral drainage via pars plana was performed by surgeon 2 (E.F.). Glaucoma drainage site was not interfered with in hope that blood residues will control the causative over drainage. At day 3 (24 h later), the patient presented again with a flat anterior chamber, a recurrent subtotal MSCH, with IOP of 45 mm Hg. The ultrasound showed a central opening in the vitreous space with remaining SCH in the 4 quadrants, mainly in the temporal area (Fig. 5). On the same day, 100 μg/0.4 mL of r-tPA was injected again into two temporal quadrants of SCH. After 6 h, the SCH was surgically drained. Intravitreal perfluorodecalin was used as a temporary tamponade and was removed 14 days later and replaced with an air tamponade. The retina and choroid remained flat postoperatively, and BCVA recovered to 6/15 at 1 year post operation.

Fig. 5.

An ultrasound of case 3, demonstrating a central opening in the vitreous space with remaining SCH in the 4 quadrants (rebleed).

Fig. 5.

An ultrasound of case 3, demonstrating a central opening in the vitreous space with remaining SCH in the 4 quadrants (rebleed).

Close modal

The results from our case series demonstrated that 100 μg/0.4 mL of r-tPA (alteplase) can be safely administered as early as 24 h following initial injury and early drainage with assisted PPV can be performed within 3 days of initial injury. This led to improved final visual acuity in all our patients. We believe this is the earliest drainage of MSCH with use of 2-step approach with use of r-tPA to our knowledge. We will discuss the learning points alongside a literature review below.

Timing of Surgical Drainage

The most effective timing for surgical drainage of SCH has not yet been confirmed. In the acute setting, surgical drainage has been shown to extend the haemorrhage into the vitreous cavity in rabbit models [19]. Subacutely, after clot formation, drainage is also likely to be ineffective and potentially unsafe if the suprachoroidal space is probed to remove residual clots [11]. Previous studies have advocated waiting for clot lysis and have consistently reported a mean time of SCH drainage between 11 and 14 days [6, 9, 11]. This is supported by ultrasound evaluation, revealing natural SCH clot lysis over 6–25 days [11]. However, in some cases, atrophic changes have developed in the choroid and retina while awaiting clot lysis [11]. Throughout our case series, we aimed to maximise visual function by early intervention and were able to initiate surgical drainage within 3 days of onset in two cases and as early as 2 days in 1 case. Early drainage may offer a better prognosis [7] and r-tPA may offer a solution to achieving this.

In case 3, drainage of the MSCH was performed 30 h after the onset with apparent anatomical success. Unfortunately, the SCH recurred on the following day. This may have happened due to over drainage by glaucoma devise, leading to flattening of anterior chamber and hypotony. However, one must also consider r-tPA promoting lysis of the thrombosed vessel. It is likely that the use of internal tamponade after draining SCH is protective from recurrence. We propose that delaying the r-tPA-assisted drainage for 6–48 h may allow more complete haemolysis and decrease the chances of recurrence of the SCH while still allowing improved visual outcome.

Dosage of r-tPA

In the systemic treatment of stroke, the r-tPA (alteplase) is administered as a thrombolytic at a dose of 900 μg/kg (max. per dose 90 mg) [20]. When used intraocularly, dosages are markedly reduced. Treatment for submacular haemorrhage using intravitreal r-tPA was first described using a dose of 12.5 μg[31]. Previous reports (Table 1) of treating SCH with r-tPA have utilised doses between 25 μg and 100 μg.

Doses above 50 μg of intravitreal r-tPA have been identified as inducing retinal toxicity in rabbit models [21]. This has also been reported to occur in humans following two 50 μg doses, 3 days apart [22]. These investigations both reported that toxicity may be related to the carrier (l-arginine) rather than r-tPA itself. The toxic reactions included pigmentary changes, retinal detachments, electroretinogram changes, and poor visual recovery. Intravitreal doses below 25 μg have not been shown to cause harm [21]. However, we hypothesise the suprachoroidal administration of r-tPA may prevent direct retinal toxicity due to presence of choroid as mechanical barrier and the blood retinal barrier, and so higher doses than 25 μg may be used. To our knowledge, there is no published literature on this.

If recognised as a useful treatment, the possibility of retinal toxicity needs to be balanced with the dose/concentration of r-tPA required to enable safe early clot lysis. Our observations suggest that a suprachoroidal injection of 100 μg r-tPA is safe.

Time Allowed for r-tPA Aided Haemolysis before Surgical Drainage

r-tPA has a short systemic half-life of 5–10 min [23]. Although animal models have found this to be 4–6 h intravitreally and 10–12 h in the presence of a fibrin clot [24]. In vitro analysis on human plasma demonstrates that fibrinolysis begins to occur around 20 min following fibrinogen/plasmin contact [25]. However, both plasmin generation and fibrinolysis are thought to be a dynamic process in vivo and clot structure is an important influence [26].

Animal models have shown that after administration of just 25 μg of tPA allowed SCH to be aspirated after just 32 min. The time was reduced to 24 min if 50 μg of tPA was administered [27]. However, the tPA was administered as depot on a sponge sewn underneath a scleral flap. Although we cannot directly compare this model, it is apparent that there is a dose dependant response of clot lysis within the suprachoroidal space. In this case series, surgical drainage of the SCH was performed between 6 and 48 h following administration of r-tPA. Complete drainage was only complete in cases 1 and 2. These two cases had the longer interval between r-tPA administration and surgical drainage (48 h). Conceivably, this effect may have occurred through the short-acting bolus administration of r-tPA initiating sufficient liquefaction for the core and distal areas of the clot to be broken up by endogenous procoagulant activity. We feel that a balanced approach would be to recommend surgical drainage in 24–48 h after the r-tPA administration.

Complications

In this series, complications occurred in only case 3. Recurrence of SCH in case 3 most likely to have happened due to over drainage by glaucoma devise leading to hypotony and may have benefitted from device removal.

Outcomes

Surgical drainage of macula-involving MSCH has been found to produce favourable anatomical outcomes [5‒7] which was confirmed in our case series. However, prognosis for functional recovery following the drainage of MSCH usually remains guarded [6]. Scott et al. [28] managed 51 patients with MSCH and found disappointing visual outcomes. 27.5% of patients have a final vision of NPL and 29.4% retained pre-haemorrhage acuity or vision greater than 20/200.

Qureshi et al. [29] from Manchester University Hospital also looked retrospectively over a 10-year period (2008–2018) at 20 patients with SCH who underwent external surgical drainage alone versus combined with PPV according to surgeon preference and clinical indication such as presence of retinal detachment or dense vitreous haemorrhage. The average time for drainage for all cases was 11 ± 6 days. Overall the mean BCVA marginally improved from 20/3,319 to 20/526. It was suggested that drainage with or without PPV was valuable in the management of these cases.

More recently, Chen et al. [30] managed 12 eyes with SCH with external drainage and PPV between 2010 and 2020. In this study, the average time for drainage was 17 days (range: 7–30 days). Once again, the mean visual outcome was poor improving from light perception to counting fingers. This further illustrates the need for early drainage to improve visual potential.

Despite the generally poor prognosis of macula-involving MSCH, 2 out of 3 patients in our cohort showed an improvement upon their presenting visual acuity following expedited drainage of the MSCH. We suggest this is due to early drainage expedited by use of r-tPA.

Limitations

Our cohort is small with various aetiologies causing MSCH. This makes the data difficult to analyse. However, we standardised the two-step operation with the timing of administration of r-tPA, as well as surgical intervention combining surgical drainage with PPV and produced favourable outcomes in 2 out of 3 cases.

Our results have shown that two-step r-tPA-assisted early drainage of macula-involving MSCH has the potential to restore some clinically useful visual function in cases with otherwise poor prognosis. Our observations lead us to believe that an appropriate dose of r-tPA would be 100 μg administered 24 h of the MSCH developing, prior to surgical drainage 24–48 h later. Our promising case series lead us to believe that further large multicentre studies are essential to establish confirmation of safety and efficacy before it can be recommended as a standard procedure for treatment of MSCH.

Written informed consent was obtained from the patient for publication of the details of their medical case and any accompanying images. Ethics approval was not required by the West of Scotland Ethics Committee as it was a retrospective study. The principles of the Declaration of Helsinki were maintained throughout the audit process.

The authors declare that there were no conflicts of interest.

The authors declare that there was no funding for this retrospective case series.

M.K. (corresponding author), M.S., M.V., J.A.D., and E.F. were involved in the writing of the study. S.S. was involved in the writing of the study, revised the article, and provided senior support.

All data generated or analysed during this study are included in this article and its online supplementary material files. Further enquiries can be directed to the corresponding author.

1.
Welch
JC
,
Spaeth
GL
,
Benson
WE
.
Massive suprachoroidal hemorrhage: follow up and outcome of 30 cases
.
Ophthalmology
.
1988
;
95
(
9
):
1202
6
.
2.
Perry
HD
,
Hsieh
RC
,
Evans
RM
.
Malignant melanoma of the choroid associated with spontaneous expulsive choroidal hemorrhage
.
Am J Ophthalmol
.
1977
;
84
(
2
):
205
8
.
3.
Reynolds
MG
,
Haimovici
R
,
Flynn
HW
,
DiBernardo
C
,
Byrne
SF
,
Feuer
W
.
Suprachoroidal hemorrhage
.
Ophthalmology
.
1993
;
100
(
4
):
460
5
.
4.
Chorich
LJ
,
Derick
RJ
,
Chambers
RB
,
Cahill
KV
,
Quartetti
EJ
,
Fry
JA
, et al
.
Hemorrhagic ocular complications associated with the use of systemic thrombolytic agents
.
Ophthalmology
.
1998
;
105
(
3
):
428
31
.
5.
Lambrou
FH
,
Meredith
TA
,
Kaplan
HJ
.
Secondary surgical management of expulsive choroidal hemorrhage
.
Arch Ophthalmol
.
1987
;
105
(
9
):
1195
8
.
6.
Meier
P
,
Wiedemann
P
.
Massive suprachoroidal hemorrhage:secondary treatment and outcome
.
Graefe’s Arch Clin Exp Ophthalmol
.
2000
;
238
(
1
):
28
32
.
7.
Gressel
MG
,
Parrish
RKII
,
Heuer
DK
.
Delayed nonexpulsive suprachoroidal hemorrhage
.
Arch Ophthalmol
.
1984
;
102
(
12
):
1757
60
.
8.
Liu
JC
,
Peyman
GA
,
Oncel
M
.
Treatment of experimental suprachoroidal hemorrhage with intravenous tissue plasminogen activator
.
Int Ophthalmol
.
1990
;
14
(
4
):
267
70
.
9.
Lavinsky
F
,
Moisseiev
J
,
Levkovitch-Verbin
H
.
The surgical management of massive intraoperative and postoperative suprachoroidal hemorrhage: anatomic and functional outcomes
.
Arq Bras Oftalmol
.
2013
;
76
(
4
):
212
4
.
10.
Wirostko
WJ
,
Han
DP
,
Mieler
WF
,
Pulido
JS
,
Connor
TB
Jr
,
Kuhn
E
.
Suprachoroidal hemorrhage: outcome of surgical management according to hemorrhage severity
.
Ophthalmology
.
1998
;
105
(
12
):
2271
5
.
11.
Chu
T
,
Green
R
.
Suprachoroidal hemorrhage
.
Surv Ophthalmol
.
1999
;
43
(
6
):
471
86
.
12.
Gurman
P
,
Miranda
OR
,
Nathan
A
,
Washington
C
,
Rosen
Y
,
Elman
NM
.
Recombinant tissue plasminogen activators (rtPA): a review
.
Clin Pharmacol Ther
.
2015
;
97
(
3
):
274
85
.
13.
Murata
T
,
Kikushima
W
,
Imai
A
,
Toriyama
Y
,
Tokimitsu
M
,
Kurokawa
T
.
Tissue-type plasminogen activator-assisted drainage of suprachoroidal hemorrhage showing a kissing configuration
.
Jpn J Ophthalmol
.
2011
;
55
(
4
):
431
2
.
14.
Fei
P
,
Jin
HY
,
Zhang
Q
,
Li
X
, et al
.
Tissue plasminogen activator-assisted vitrectomy inthe early treatment of acute massive suprachoroidal hemorrhage complicating cataract surgery
.
Int J Ophtalmol
.
2017
;
11
(
1
):
170
1
.
15.
Matsumoto
K
,
Matsumoto
CS
,
Shinoda
K
,
Watanabe
E
,
Mizota
A
.
Tissue plasminogen activator-assisted vitrectomy for ruptured eye with suprachoroidal hemorrhage
.
Case Rep Ophthalmol
.
2012
;
3
(
2
):
258
61
.
16.
Kunjukunju
N
,
Gonzales
CR
,
Rodden
WS
.
Recombinant tissue plasminogen activatorin the treatment of suprachoroidal hemorrhage
.
Clin Ophthalmol
.
2011
;
5
:
155
7
.
17.
Murata
T
,
Kikushima
W
,
Imai
A
,
Toriyama
Y
,
Tokimitsu
M
,
Kurokawa
T
.
Tissue-type plasminogen activator-assisted drainage of suprachoroidal hemorrhage showing a kissing configuration
.
Jpn J Ophthalmol
.
2011
;
55
(
4
):
431
2
.
18.
Akram
H
,
Dowlut
MS
,
Chandra
A
.
Suprachoroidal Haemorrhage (SCH) drainage using suprachoroidal tissue Plasminogen Activator (t-PA) after complicated cataract extraction (two-staged procedure): early intervention could mean better vision
.
BMJ Case Rep
.
2021
;
14
(
5
):
e241705
.
19.
Lakhanpal
V
.
Experimental and clinical observations on massive suprachoroidal hemorrhage
.
Trans Am Ophthalmol Soc
.
1993
;
91
:
545
652
.
20.
Joint Formulary Committee
.
British national formulary (online)
.
London
:
BMJ group and pharmaceutical press
. https://bnf.nice.org.uk/drug/alteplase.html (Accessed on October 10, 2019).
21.
Johnson
MW
,
Olsen
KR
,
Hernandez
E
,
Irvine
WD
,
Johnson
RN
.
Retinal toxicity of recombinant tissue plasminogen activator in the rabbit
.
Arch Ophthalmol
.
1990
;
108
(
2
):
259
63
.
22.
Chen
SN
,
Yang
TC
,
Ho
CL
,
Kuo
YH
,
Yip
Y
,
Chao
AN
.
Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review
.
Ophthalmology
.
2003
;
110
(
4
):
704
8
.
23.
Kamei
M
,
Estafanous
M
,
Lewis
H
.
Tissue plasminogen activator in the treatment of vitreoretinal diseases
.
Semin Ophthalmol
.
2000
;
15
(
1
):
44
50
.
24.
Jaffe
GJ
,
Green
GD
,
McKay
BS
,
Hartz
A
,
Williams
GA
.
Intravitreal clearance of tissue plasminogen activator in the rabbit
.
Arch Ophthalmol
.
1988
;
106
(
7
):
969
72
.
25.
Gabriel
DA
,
Muga
K
,
Boothroyd
EM
.
The effect of fibrin structure on fibrinolysis
.
J Biol Chem
.
1992
;
267
(
34
):
24259
63
.
26.
Wolberg
AS
.
Thrombin generation and fibrin clot structure
.
Blood Rev
.
2007
;
21
(
3
):
131
42
.
27.
Kwon
OW
,
Kang
SJ
,
Lee
JB
,
Lee
SC
,
Yoon
YD
,
Oh
JH
.
Treatment of suprachoroidal hemorrhage with tissue plasminogen activator
.
Ophthalmologica
.
1998
;
212
(
2
):
120
5
.
28.
Scott
IU
,
Flynn
HW
,
Schiffman
J
,
Smiddy
WE
,
Murray
TG
,
Ehlies
F
.
Visual acuity outcomes among patients with appositional suprachoroidal hemorrhage
.
Ophthalmology
.
1997
;
104
(
12
):
2039
46
.
29.
Qureshi
A
,
Jalil
A
,
Sousa
DC
,
Patton
N
,
Dhawahir-Scala
F
,
Charles
SJ
, et al
.
Outcomes of suprachoroidal haemorrhage drainage with and without vitrectomy: a 10-year study
.
Eye
.
2021
;
35
(
7
):
1879
85
.
30.
Chen
X
,
Hou
B
,
Yin
L
,
Wang
F
.
Treatment of massive suprachoroidal hemorrhage by drainage surgery with vitrectomy: experience of a single center
.
Semin Ophthalmol
.
2022
;
37
(
6
):
767
773
.
31.
Herriot
WJ
.
Intravitreal Gas and TPA: An Outpatient Procedure for Submacular Hemorrhage. AAO Annual Vitreoretinal Update. Chicago, IL, USA, 1996
.